166 related articles for article (PubMed ID: 19734970)
1. Immunotherapy with wasp venom is accompanied by wide-ranging immune responses that need further exploration.
Brasch J; Maidusch T
Acta Derm Venereol; 2009; 89(5):466-9. PubMed ID: 19734970
[TBL] [Abstract][Full Text] [Related]
2. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
[TBL] [Abstract][Full Text] [Related]
3. [Value of specific IgE and IgG4 measurements in the follow-up of a hymenoptera venom immunotherapy treatment: apropos of 82 cases].
Sonneville A; Loustanau O; Tahar HA; Menelet I
Allerg Immunol (Paris); 2000 Jan; 32(1):20-5. PubMed ID: 10723532
[TBL] [Abstract][Full Text] [Related]
4. Expansion of circulating Foxp3+)D25bright CD4+ T cells during specific venom immunotherapy.
Pereira-Santos MC; Baptista AP; Melo A; Alves RR; Soares RS; Pedro E; Pereira-Barbosa M; Victorino RM; Sousa AE
Clin Exp Allergy; 2008 Feb; 38(2):291-7. PubMed ID: 18070166
[TBL] [Abstract][Full Text] [Related]
5. Specific ultrarush desensitization in Hymenoptera venom-allergic patients.
Schiavino D; Nucera E; Pollastrini E; De Pasquale T; Buonomo A; Bartolozzi F; Lombardo C; Roncallo C; Patriarca G
Ann Allergy Asthma Immunol; 2004 Apr; 92(4):409-13. PubMed ID: 15104191
[TBL] [Abstract][Full Text] [Related]
6. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects.
Bellinghausen I; Metz G; Enk AH; Christmann S; Knop J; Saloga J
Eur J Immunol; 1997 May; 27(5):1131-9. PubMed ID: 9174602
[TBL] [Abstract][Full Text] [Related]
7. Alternating Polistes-Vespula venom immunotherapy: a therapeutic strategy to resolve a diagnostic deficiency.
Moreno C; Barasona MJ; Serrano P; Justicia JL; Ruz JM; Guerra F
J Investig Allergol Clin Immunol; 2011; 21(1):28-33. PubMed ID: 21370720
[TBL] [Abstract][Full Text] [Related]
8. Follow-up of venom immunotherapy (VIT) based on conventional techniques and monitoring of immunoglobulin E to individual venom allergens.
Carballada F; Boquete M; Núñez R; Lombardero M; de la Torre F
J Investig Allergol Clin Immunol; 2010; 20(6):506-13. PubMed ID: 21243935
[TBL] [Abstract][Full Text] [Related]
9. [Allergic reactions to insect bites].
Urbanek R
Ther Umsch; 1989 Sep; 46(9):654-62. PubMed ID: 2678576
[TBL] [Abstract][Full Text] [Related]
10. Humoral immunological response in patients with venom allergy during specific immunotherapy.
Szymański W; Chyrek-Borowska S
Rocz Akad Med Bialymst; 1995; 40(2):376-82. PubMed ID: 8834621
[TBL] [Abstract][Full Text] [Related]
11. [Basophil degranulation test (BDT) as a parameter of hyposensitization with Hymenoptera venoms].
Dietschi R; Wüthrich B; Marti-Wyss S; Cuhat J
Schweiz Med Wochenschr; 1987 Oct; 117(44):1728-35. PubMed ID: 3685930
[TBL] [Abstract][Full Text] [Related]
12. Basophil sensitivity in patients not responding to venom immunotherapy.
Peternelj A; Silar M; Erzen R; Kosnik M; Korosec P
Int Arch Allergy Immunol; 2008; 146(3):248-54. PubMed ID: 18270492
[TBL] [Abstract][Full Text] [Related]
13. Sublingual desensitization in patients with wasp venom allergy: preliminary results.
Patriarca G; Nucera E; Roncallo C; Aruanno A; Lombardo C; Decinti M; Pascolini L; Milani M; Buonomo A; Schiavino D
Int J Immunopathol Pharmacol; 2008; 21(3):669-77. PubMed ID: 18831935
[TBL] [Abstract][Full Text] [Related]
14. Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy.
Dugas-Breit S; Przybilla B; Dugas M; Arnold A; Pfundstein G; Küchenhoff H; Ruëff F
Clin Exp Allergy; 2010 Apr; 40(4):643-9. PubMed ID: 20100187
[TBL] [Abstract][Full Text] [Related]
15. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.
Goldberg A; Confino-Cohen R
J Allergy Clin Immunol; 2001 May; 107(5):902-6. PubMed ID: 11344360
[TBL] [Abstract][Full Text] [Related]
16. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients.
Lerch E; Müller UR
J Allergy Clin Immunol; 1998 May; 101(5):606-12. PubMed ID: 9600496
[TBL] [Abstract][Full Text] [Related]
17. Allergen-specific immunosuppression by mucosal treatment with recombinant Ves v 5, a major allergen of Vespula vulgaris venom, in a murine model of wasp venom allergy.
Winkler B; Bolwig C; Seppälä U; Spangfort MD; Ebner C; Wiedermann U
Immunology; 2003 Nov; 110(3):376-85. PubMed ID: 14632666
[TBL] [Abstract][Full Text] [Related]
18. Case report of venom immunotherapy for a patient with large local reactions.
Hamilton RG; Golden DB; Kagey-Sobotka A; Lichtenstein LM
Ann Allergy Asthma Immunol; 2001 Aug; 87(2):134-7. PubMed ID: 11527245
[TBL] [Abstract][Full Text] [Related]
19. Development of new IgE specificities to hymenoptera allergens during venom-specific immunotherapy.
Tavares B; Rordigues F; Pereira C; Loureiro G; Chieira C
Eur Ann Allergy Clin Immunol; 2005 May; 37(5):171-6. PubMed ID: 15984315
[TBL] [Abstract][Full Text] [Related]
20. Decline of Ves v 5-specific blocking capacity in wasp venom-allergic patients after stopping allergen immunotherapy.
Möbs C; Müller J; Rudzio A; Pickert J; Blank S; Jakob T; Spillner E; Pfützner W
Allergy; 2015 Jun; 70(6):715-9. PubMed ID: 25753563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
